Johnson & Johnson (JNJ) has announced its plan to purchase Halda Therapeutics, a firm focused on developing oral therapies aimed at treating various solid tumors, for $3.05B in cash.
The company anticipates a dilution of $0.15 to its adjusted earnings per share in 2026. This is attributed to short-term financing and a one-time charge related to equity awards for Halda’s employees upon the deal’s completion.
Halda’s leading candidate, HLD-0915, is currently in clinical stages for treating prostate cancer.
The company said the deal is expected to finalize in the coming months, pending antitrust approval and other standard closing conditions.